Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Insulin Delivery Mar 07 | 2022BD Spinoff Embecta Hosts Virtual Investor Event; Discloses Insulin Patch Pump Program for T2DMPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Mar 04 | 2022Beta Bionics Management Changes Ahead of Insulin-only iLet Bionic Pancreas Launch; Glooko Partners with Johns HopkinsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Mar 03 | 2022Novo 2022 Capital Markets Day Highlights and AnalysisPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Other, SGLT2i Mar 02 | 2022Jardiance EMPULSE Trial Published; Senseonics Q4 ’21 Earnings Update; Novo Initiates Icosema COMBINE 2 Ph3 Trial; Merck’s Oral PCSK9i Enters Ph2; BI Partners with Lifebit; Intercept and Amarin Q4 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 01 | 2022Roxa US Regulatory Path Remains Unclear; Bayer Q4 ’21 Earnings Update; Dexcom’s Hospital CGM Receives Breakthrough Device Designation; Teladoc and Amazon Alexa Collaboration; Dario and Sanofi CollaborationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other, SGLT2i Feb 28 | 2022Lexicon Faces Another Sota Setback; Biocon to Acquire Viatris Biosimilars Business; Viatris Confirms Generic Ozempic FilingPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Feb 25 | 2022Lilly Moves Forward with Dicerna ANGPTL3 Asset; Ionis and MannKind Q4 ’21 and FY ’21 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Feb 24 | 2022EMPEROR-Preserved Approved by FDA; Wegovy Supply Restored for Existing US Patients; Provention Bio Q4 and FY ’21 Earnings Update; Omada Closes $192M Series EPurchase Blast
$599
Posted in: Other, SGLT2i Feb 24 | 2022Bayer Initiates Kerendia and Jardiance Combo Trial Following Kerendia EU ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 23 | 2022Insulet FY ’21 Earnings Update; Novo Partners with Vonage for IO Customer Support; Esperion, Teladoc, and Adocia Q4 ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Feb 23 | 2022Provention Bio Refiles Teplizumab BLA; Medtronic and Tandem Q4 ’21 and FY ’21 Earnings Updates; Lilly Invests $700M in New Lilly Institute for Genetic Medicine; RosVivo Therapeutics and Lilly Sign MTA for RSVI-301; February 21-24 CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Feb 18 | 2022ICER Report Questions Tirzepatide’s Effectiveness Compared to Ozempic and Jardiance; Signos and Dexcom to Launch CGM+AI-Enhanced App Trial; Teladoc Launches Chronic Care Complete Program; Movano Completes Second Glucose Pilot Study; Better Therapeutic Enrolls First Patient in BT-001 RWE StudyPurchase Blast
$599
Posted in: Insulin Delivery, Other Feb 17 | 2022Insulet Partners with Nintendo’s Animal Crossing Game; Beta Bionics Raises $57M in Series C FinancingPurchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Other Feb 16 | 2022Tandem’s Mobile Bolus Feature Cleared by FDAPurchase Blast
$599
Posted in: Other, SGLT2i Feb 15 | 2022Novo Sues Teva Over Generic Saxenda; Cytokinetics Announces Disappointing METEORIC-HF Results; Zealand’s Pediatric Ph3 Dasiglucagon in CHI Trial Completes EnrollmentPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 14 | 2022Nemaura CY Q4 ‘21 and FY ’21 (FY Q3 ‘22) Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 11 | 2022Will AZ Fund an Additional Roxa Trial?; Senseonics Eversense E3 CGM Receives FDA ApprovalPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 10 | 2022Dexcom Q4 ‘21 and FY ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Feb 10 | 2022AZ Q4 '21 and FY '21 Earnings UpdatePurchase Blast